Zymeworks (ZYME) Current Deferred Revenue (2021 - 2026)

Zymeworks (ZYME) has 6 years of Current Deferred Revenue data on file, last reported at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 94.55% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (down 94.55% YoY), and the FY2025 full-year result was $2.4 million, down 90.55% from the prior year.
• Current Deferred Revenue retreated to $2.1 million in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $41.8 million in Q3 2024 to a low of $93000.0 in Q3 2023.
• A 5-year average of $16.7 million and a median of $3.8 million in 2025 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue plunged 99.72% in 2023 and surged 44840.86% in 2024, its largest moves.
• Tracing ZYME's Current Deferred Revenue over 5 years: stood at $2.4 million in 2022, then surged by 57.25% to $3.7 million in 2023, then surged by 591.89% to $25.6 million in 2024, then sank by 90.55% to $2.4 million in 2025, then fell by 14.06% to $2.1 million in 2026.
• Business Quant data shows ZYME's Current Deferred Revenue at $2.1 million in Q1 2026, $2.4 million in Q4 2025, and $3.2 million in Q3 2025.